Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure

Biomed Pharmacother. 2023 Aug:164:114906. doi: 10.1016/j.biopha.2023.114906. Epub 2023 Jun 7.

Abstract

The impact of body mass index (BMI) on treatment outcomes in patients with cancer is gaining increasing attention given the limited data available. The aim of this study was to investigate the contribution of BMI on the safety and efficacy profile of palbociclib in 134 patients with metastatic luminal-like breast cancer treated with palbociclib and endocrine therapy (ET). Normal-weight and underweight patients (BMI<25) were compared with overweight and obese (BMI≥25). Detailed clinical and demographic data were collected. Patients with a BMI<25 had a higher incidence of relevant-hematologic toxicities (p = 0.001), dose reduction events (p = 0.003), and tolerated lower dose intensities (p = 0.023) compared to patients with a BMI≥25. In addition, patients with a BMI<25 had significantly shorter progression-free survival (log-rank p = 0.0332). A significant difference was observed in the subgroup of patients for whom systemic palbociclib concentrations were available: patients with a BMI<25 had a 25% higher median minimum plasma concentrations (Cmin) compared to BMI≥25. This study provides compelling evidence for a clinically relevant contribution of BMI in discriminating a group of patients who experienced multiple toxicities that appeared to affect treatment adherence and lead to poorer survival. BMI could become a valuable tool for personalizing the starting dose of palbociclib to improve its safety and efficacy.

Keywords: Body mass index; HER-negative breast cancer; Hormon receptor-positive; Palbociclib; Progression free survival; Treatment adherence.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Body Mass Index
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Receptor, ErbB-2
  • Treatment Outcome

Substances

  • palbociclib
  • Receptor, ErbB-2